Itraconazole-enhanced vindesine neurotoxicity in adult acute lymphoblastic leukaemia.
Chen
Suning
S
Wu
Depei
D
Sun
Aining
A
Qiu
Huiying
H
Jin
Zhengming
Z
Tang
Xiaowen
X
Miao
Miao
M
Fu
Zhengzheng
Z
Ma
Xiao
X
Han
Yue
Y
Hu
Xiaohui
X
D000328:Adult; D000935:Antifungal Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004357:Drug Synergism; D017809:Fatal Outcome; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D007418:Intestinal Pseudo-Obstruction / Q000139:chemically induced*; D017964:Itraconazole / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000601:surgery; D011239:Prednisolone / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage; D014751:Vindesine / Q000008:administration & dosage / Q000009:adverse effects*
D000935:Antifungal Agents; D017964:Itraconazole; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; D014751:Vindesine; D015255:Idarubicin